Category - Markets

Analysts at Stifel and BTIG initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with “buy” ratings and price targets of $18 and $20, respectively. The stock closed at $13.80 on Friday. “Obalon appears poised for...

Maxim Group downgraded Opexa Therapeutics (NASDAQ:OPXA) to “hold” from “buy” and removed its previous price target of $18 after the company failed a Phase 2b trial in secondary progressive multiple sclerosis (SPMS). The...

Canaccord Genuity raised its price target for AtriCure (NASDAQ:ATRC) to $23 from $21 after the company reported third quarter results. The stock is trading at $17.74, up $2.54, at midday on Friday. The third quarter...

H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday. Analyst Swayampakula Ramakanth writes that during Agenus’ third...

Canaccord Genuity raised its price target for CryoLife (NYSE:CRY) to $23.50 from $17.50 after the company reported third quarter results. The stock is changing hands at $17.10 on Thursday afternoon. Analyst Jason Mills...

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral,” with a price target of $10, after the company reported third quarter results. The stock closed at $7.13 on Wednesday. “When we downgraded shares at $9, our...

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a ‘buy” rating and $15 price target. The stock closed at $8.86 on Friday. “While the genetic testing market is not without challenges and competition is...

Stifel launched coverage of Tabula Rasa HealthCare (NASDAQ:TRHC) with a “buy” rating and $17 price target. The stock closed at $14.23 on Friday. Tabula is a healthcare information technology company focused on...

Stifel initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with a “buy” rating and $18 price target. The stock closed at $8.35 on Oct. 20. Analyst Stephen Willey writes that Xenon has successfully leveraged its...

Leerink initiated coverage of AC Immune SA (NASDAQ:ACIU) with an “outperform” rating and $22 price target. The stock closed at $14.43 on Friday. AC Immune is focused on developing novel medicines for neurodegenerative...